Biotech Analysis Central: Daily Pharma News - October 17, 2017


Bristol-Myers Squibb achieves encouraging data in small cell lung cancer patients with both Opdivo alone and in combination with Yervoy Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. News: On Monday, Exelixis with its partner Ipsen announced that its phase 3 trial, known as CELESTIAL, met its primary endpoint of overall survival .



from Biotech News